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assessed with WHO DTSQ. Use of InDuo also resulted in sig-
niﬁcantly higher rating of insulin therapy, lack of interference
with lifestyle and ease of injecting when away from home.
Seventy-nine percent patients preferred treatment with InDuo
rather than SVM, with convenience, ease of use, and accuracy
being major factors (p < 0.001). Other important features that
resulted in testing of BG more often with InDuo than with a
SVM included speciﬁc features like the 5-second BG analysis
(60%) and small blood sample requirement (55%). For InDuo
91% used BG memory several times a week (66% used doser
memory several times a week). Overall, the enrolled population
showed a signiﬁcant mean reduction of 0.54% in the A1C values
(p < 0.0001). Using combination device a large subset of patients
(32%) showed substantial increases in frequency of daily SMBG
monitoring (Mean 1 more reading/day). CONCLUSIONS: Use
of the InDuo was associated with improvements in patient treat-
ment satisfaction, which were reﬂected, in improved compliance
(more injections or blood tests per day) in a substantial portion
of the patients tested.
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OBJECTIVES: To examine admissions within the VA facility
among veterans with diabetes and the relationship between
number of admissions and type of antidiabetic therapy.
METHODS: Veterans with diabetes mellitus at a Texas Veterans
Health care System were selected by identifying those with an
ICD-9 code for diabetes from the outpatient ﬁle. Veterans who
received continuous care at the VA from FY 2000 to 2002 were
selected. Local Patient Treatment File and pharmacy ﬁle pro-
vided information on all VA admissions and prescription data.
A published method on attributing hospital utilization to dia-
betes based on ICD-9 codes and codes for diagnostic-related
groups from administrative databases were used. This method
classiﬁes admissions into 3 categories: clearly attributable to dia-
betes; probably attributable to diabetes; or not attributable to
diabetes. Type of medication therapy was deﬁned as the follow-
ing: oral therapy all 3 years; oral and insulin; insulin only; esca-
lating therapy; and other (i.e. insulin to oral or oral to no
medication). RESULTS: Of the 2285 veterans included in the
study, there were 1687 admissions at the VA facility over the 3-
year period. A total of 772 patients accounted for the admis-
sions. The mean length of stay per admission was 5.34 days (+/-
5.01). Of the admissions, 106 (6.4%) were clearly attributable
to diabetes; 578 (35.1%) were probably attributable to diabetes
and 964 (58.5%) were not attributable to diabetes. Comparisons
showed that mean rank for number of admissions for those on
oral therapy only was signiﬁcantly lower than the following:
both insulin and oral (Z = -5.43, p < 0.005); insulin only (Z =
-4.36, p < 0.005); escalating therapy (Z = -6.67, p < 0.005) and
other (Z = -7.01, p < 0.005). CONCLUSIONS: Approximately
40% of admissions among veterans with diabetes were either
clearly attributable or probably attributable to diabetes. Receiv-
ing oral therapy only was associated with fewer number of hos-
pital admissions than those on more intense therapy.
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OBJECTIVE: Glycemic control is a clinical outcome variable
often used in diabetes intervention research. Misconceptions
about A1C (glycosylated hemoglobin) and GHb (glycated hemo-
globin) measures can lead to the use of different glycemic control
measures within a study, threatening reliability and validity of
outcomes results. While A1C is the standard for long-term
glycemic control, the GHb measure may be more appropriate
among patients with hemoglobin variants like the sickle cell
factor and is sometimes used by clinicians who are aware that
their patient population has prevalence of these variants. GHb
measures are generally higher than A1Cs. The objective of this
study was to examine the impact on outcomes results of using
data from mixed (A1C or GHb) sites. METHODS: A conve-
nience sample of 183 patients from four patient care sites par-
ticipated in a cross-sectional survey measuring self-care
behaviors, diabetes history, and demographics. Glycemic control
data were gathered from patient charts and aggregated; one site
used GHb. Aggregated glycemic control data were analyzed with
other study variables. The GHb data were then converted to A1C
equivalents using a regression formula provided by the National
Glycohemoglobin Standardization Program (NGSP); analyses
were conducted again and compared. RESULTS: Mean glycemic
control for the sample with unconverted GHb readings was
8.40% (sd = 2.79); the mean for the A1C converted sample was
7.84% (sd = 1.89). Signiﬁcance of variable relationships varied
between the two, and the magnitude of relationship among 
correlated variables was greater among the unconverted GHb
sample. Mean glycemic control for both analyses revealed sta-
tistically signiﬁcant associations (p < 0.05) with readiness for all
diabetes self-care behaviors except vigorous exercise, but vari-
able associations among the group with unconverted GHbs were
stronger. CONCLUSIONS: If data within a study include dif-
ferent or non-standardized glycemic control measures, they
should be converted to be sure results reﬂect a standard variable.
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OBJECTIVES: The purpose of this study was to validate a dia-
betes resource consumption index (DRCI). METHODS: The
data for this study was collected from the Southern Arizona Vet-
erans Affairs Health care System. A random split study sample
was created from the computerized medical record of veterans
with diabetes. Model estimation was done on the ﬁrst sample (n
= 367) and validation using the other 50% of the sample (n =
367). A Fisher’s z-statistic was used to assess the degree of 
correspondence between the predicted and actual values
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obtained from the derivation versus the validation samples. The
construct validity of the DRCI was assessed by comparing it to
only demographics, a comorbidity-index, and the revised
Chronic Disease Score (CDS). Wilcoxon matched-pairs signed-
rank test was used to determine differences between the median
squared residual scores between the various risk-adjustment
models. RESULTS: The correlation between actual and predicted
costs between the derivation and validation samples was not sta-
tistically different for the three predicted outcomes. Age and sex
accounted for 0.8% and 0.1% of the variance in total and ambu-
latory cost. The comorbidity index and the CDS individually
explained approximately 6%–10% of the variance in total and
ambulatory cost, respectively. The DRCI explained 6%–8% of
the variance in total and ambulatory costs, and did signiﬁcantly
(p < 0.05) better than only demographics. The added variance
explained by the incorporation of the comorbidity index or CDS
accounted for 5%–8% of the variance in total and ambulatory
costs, respectively. CONCLUSIONS: The predictive validity of
the DRCI is equivalent to that of the CDS. When the DRCI was
used along with the CDS, up to eight percent of variability in
costs and utilization were explained. This may suggest that the
DRCI and the CDS may be explaining different dimensions of a
subject’s severity of diabetes.
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OBJECTIVES: The ﬁfth leading cause of death by disease in the
U.S., type-2 diabetes places patients at higher risk for heart
disease, blindness, kidney failure, extremity amputations, and
other chronic conditions. The 2002 costs associated with dia-
betes were estimated at US$132 billion. Predictive models incor-
porating clinical measures of diabetes severity from clinical
databases and their association to health care resource use and
costs are needed for health plan resource planning and man-
agement. The purpose of this study was to determine the 
relationship between health care resource use and costs with dia-
betes-related clinical measures, and to develop a diabetes
resource consumption index (DRCI). The DRCI consists of
empirically derived weights to predict health care use among
persons with diabetes. METHODS: The data was collected from
four outpatient clinics within the Southern Arizona Veterans
Affairs Health care System. The DRCI models used diabetes
severity measures to predict three health care resource outcomes:
risk of hospitalization; total health care costs; and ambulatory
costs. Severity of diabetes was deﬁned as the function of annual
HbA1C, creatinine clearance-rate, and cholesterol values.
Comorbidity was deﬁned as the number of concurrent secondary
diseases. The log-likelihood ratio test and the Wald test-statistic
were used to assess the performance of the models. RESULTS:
A total of 367 diabetic subjects had complete information on
diabetes-speciﬁc variables and represented the sample for this
study. DRCI weights based on the magnitude of one year health
care resource use and socio-demographic characteristics, ranged
from -471.5 to 3081.2 for total health care costs, from -304.3
to 1582.1 for outpatient costs, and -0.19 to 0.93 for risk of 
hospitalization. The DRCI models predicted 7% and 9% of 
the variance in total and ambulatory costs, respectively. 
CONCLUSIONS: This study suggests an association between
clinical measures of diabetes severity and health care resource
and costs. Future studies are needed to validate this index in
other settings.
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OBJECTIVES: We determined rates of gastrointestinal (GI) 
complications among patients receiving nonsteroidal anti-
inﬂammatory drugs (NSAIDS), according to risk of GI events
and adherence to Veterans Affairs (VA) NSAID prescribing
guidelines; and calculated the associated costs of hospitalizations
from GI events by risk and adherence to guidelines. METHODS:
In November 2001, we identiﬁed 7625 patients treated with
NSAIDS in the New Mexico VA Health Care System. Using VA
prescribing guidelines we assessed each patient’s risk for GI
events (low, moderate, high) and whether their treatment
adhered to VA prescribing guidelines. We then reviewed patient
records for GI hospitalizations and diagnoses within the follow-
ing 2 years. Our data included demographic information, hos-
pitalizations, prescription medications, and diagnoses. Costs
were based upon 2002 Medicare reimbursement values. We com-
pared outcomes and costs by risk level and adherence to guide-
lines, using chi square analyses for categorical data and t-tests
for costs. RESULTS: Patients at moderate and high risk (n =
2288) had more (p < 0.001) GI hospitalizations (1.86%), com-
pared to patients at low risk (n = 5337, 0.83%) with an odds
ratio of 2.24, 95% conﬁdence interval 1.47–3.41. Adherence to
guidelines was not associated with fewer hospitalizations (odds
ratio 1.41, conﬁdence interval 0.67–2.96). Among patients at
moderate-risk who were hospitalized, non-adherence to criteria
(n = 26) was associated with higher (p = 0.027) mean costs
($5709 ± 2991) compared to those adherent to criteria (n = 9,
$4037 ± 1248). Additional hospitalization costs due to non-
adherence totaled $112,099. CONCLUSION: The VA guidelines
used to assess risk of GI complications from NSAIDS was 
related to rates of GI hospitalizations over a 2-year follow-
up period. Rates of hospitalizations were not affected by 
adherence to guidelines. However, mean hospitalization costs
were signiﬁcantly lower among patients at moderate risk who
were prescribed according to guidelines. Limitations are that 
the study is observational and that costs are limited to GI 
hospitalizations.
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With a prevalence in Western countries of around 15%, GORD
is associated with considerable long-term morbidity and treat-
ment costs. Since the introduction of laparoscopic surgery in the
1990s fundoplication has becomes a viable alternative to long-
term drug therapy in difﬁcult to treat patients. Partial fundopli-
